Late-breaking results of ORIGIN Phase 2b trial supporting further evaluation of atacicept 150 mg as a potential disease-modifying treatment for IgAN will be presented at 60th European Renal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results